Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
December 27 2021 - 7:00AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced that
Dr. Neal Walker, President and CEO of Aclaris, will participate in
a fireside chat at the H.C. Wainwright BioConnect Virtual
Conference, which will be available beginning on Monday, January
10, 2022 at 7:00 a.m. ET.
A webcast of the fireside chat may be accessed through the
“Events” page of the “Investors” section of Aclaris’ website,
www.aclaristx.com. The webcast will be archived for at least 30
days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates to address the needs of patients with
immuno-inflammatory diseases who lack satisfactory treatment
options. The company has a multi-stage portfolio of drug candidates
powered by a robust R&D engine exploring protein kinase
regulation. For additional information, please visit
www.aclaristx.com.
Aclaris Contact
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024